Abstract
Coronavirus disease 2019 (COVID-19) has infected people all over the world. While scientists are busy finding a vaccine and medicine, it becomes difficult to control the spread and manage patients. Mathematical models help one get a better feel for the challenges in patient management. With this in mind, our team developed a model called Multilevel Integrated Model with a Novel Systems Approach (MIMANSA) Welling et. al (2020). MIMANSA is a multi-parametric model. One of the challenges in the design of MIMANSA was to simulate the incubation period of coronavirus. The incubation period decides when virus-infected patients would show symptoms. The probability distribution function (PDF), when applied to the number of virus-infected cases, gives a good representation of the process of the incubation period. The probability distribution functions can take various forms. In this paper, we explore a variety of PDFs and their impact on parameter estimation in the MIMANSA model. For our experiments, we used Weibull, Gaussian, uniform, and Gamma distribution. To ensure a fair comparison of Weibull, Gaussian, and Gamma distribution, we matched the peak value of the distribution. Our results show that the Weibull distribution with shape 7.7 and scale 7 for 14 days gives a better training model and predictions.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
None
Funding Statement
Pi Innovate, Pune, India
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not required
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
